ReP USP - Resultado da busca

Artigo de periodico
Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression (2021)
Leão, Matheus de Castro; Pohlmann, Adriana Raffin ; Alves, Aline de Cristo Soares; Farsky, Sandra Helena Poliselli ; Uchiyama, Mayara Klimuk ; Araki, Koiti ; Sandri, Silvana; Guterres, Sílvia Stanisçuaski ; Castro, Inar Alves de
Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidades: FCF, IQ
Subjects: ARTERIOSCLEROSE, ESTRESSE OXIDATIVO, ÁCIDOS GRAXOS OMEGA 3, NANOTECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEÃO, Matheus de Castro et al. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. European Journal of Pharmaceutics and Biopharmaceutics, v. 159, p. 99–107, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ejpb.2020.12.016. Acesso em: 15 nov. 2024.
APA
Leão, M. de C., Pohlmann, A. R., Alves, A. de C. S., Farsky, S. H. P., Uchiyama, M. K., Araki, K., et al. (2021). Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. European Journal of Pharmaceutics and Biopharmaceutics, 159, 99–107. doi:10.1016/j.ejpb.2020.12.016
NLM
Leão M de C, Pohlmann AR, Alves A de CS, Farsky SHP, Uchiyama MK, Araki K, Sandri S, Guterres SS, Castro IA de. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 159 99–107.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.ejpb.2020.12.016
Vancouver
Leão M de C, Pohlmann AR, Alves A de CS, Farsky SHP, Uchiyama MK, Araki K, Sandri S, Guterres SS, Castro IA de. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 159 99–107.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.ejpb.2020.12.016
Trabalho de evento-resumo periodico
Toxicity evaluation of docosahexaenoic acid nanoencapsulated with anti-PECAM-1 (2021)
Leão, Matheus de Castro; Pohlmann, Adriana Raffin ; Farsky, Sandra Helena Poliselli ; Broering, Milena Fronza; Castro, Inar Alves de ; Guterres, Sílvia Stanisçuaski
Source: Atherosclerosis. Conference titles: Congress European Atherosclerosis Society/EAS. Unidade: FCF
Subjects: ARTERIOSCLEROSE, MACRÓFAGOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEÃO, Matheus de Castro et al. Toxicity evaluation of docosahexaenoic acid nanoencapsulated with anti-PECAM-1. Atherosclerosis. Clare: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://pdf.sciencedirectassets.com/271064/1-s2.0-S0021915021X00147/1-s2.0-S0021915021004846/main.pdf? Acesso em: 15 nov. 2024. , 2021
APA
Leão, M. de C., Pohlmann, A. R., Farsky, S. H. P., Broering, M. F., Castro, I. A. de, & Guterres, S. S. (2021). Toxicity evaluation of docosahexaenoic acid nanoencapsulated with anti-PECAM-1. Atherosclerosis. Clare: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Recuperado de https://pdf.sciencedirectassets.com/271064/1-s2.0-S0021915021X00147/1-s2.0-S0021915021004846/main.pdf?
NLM
Leão M de C, Pohlmann AR, Farsky SHP, Broering MF, Castro IA de, Guterres SS. Toxicity evaluation of docosahexaenoic acid nanoencapsulated with anti-PECAM-1 [Internet]. Atherosclerosis. 2021 ; 331 e73 res. P053.[citado 2024 nov. 15 ] Available from: https://pdf.sciencedirectassets.com/271064/1-s2.0-S0021915021X00147/1-s2.0-S0021915021004846/main.pdf?
Vancouver
Leão M de C, Pohlmann AR, Farsky SHP, Broering MF, Castro IA de, Guterres SS. Toxicity evaluation of docosahexaenoic acid nanoencapsulated with anti-PECAM-1 [Internet]. Atherosclerosis. 2021 ; 331 e73 res. P053.[citado 2024 nov. 15 ] Available from: https://pdf.sciencedirectassets.com/271064/1-s2.0-S0021915021X00147/1-s2.0-S0021915021004846/main.pdf?
Artigo de periodico
Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis (2021)
Ortega, Juliana Festa; Heidor, Renato ; Auriemo, Ana Paula; Affonso, Juliana Marques; D’Amico, Thais; Herz, Corinna; Conti, Aline de ; Ract, Juliana Neves Rodrigues ; Gioielli, Luiz Antonio ; Purgatto, Eduardo ; Lamy, Evelyn; Pogribny, Igor; Moreno, Fernando Salvador
Source: Carcinogenesis. Unidade: FCF
Subjects: LIPÍDEOS, DANO AO DNA, CARCINOGÊNESE, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ORTEGA, Juliana Festa et al. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. Carcinogenesis, v. 42, n. 8, p. 1026–1036, 2021Tradução . . Disponível em: https://doi.org/10.1093/carcin/bgab039. Acesso em: 15 nov. 2024.
APA
Ortega, J. F., Heidor, R., Auriemo, A. P., Affonso, J. M., D’Amico, T., Herz, C., et al. (2021). Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. Carcinogenesis, 42( 8), 1026–1036. doi:10.1093/carcin/bgab039
NLM
Ortega JF, Heidor R, Auriemo AP, Affonso JM, D’Amico T, Herz C, Conti A de, Ract JNR, Gioielli LA, Purgatto E, Lamy E, Pogribny I, Moreno FS. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis [Internet]. Carcinogenesis. 2021 ; 42( 8): 1026–1036.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1093/carcin/bgab039
Vancouver
Ortega JF, Heidor R, Auriemo AP, Affonso JM, D’Amico T, Herz C, Conti A de, Ract JNR, Gioielli LA, Purgatto E, Lamy E, Pogribny I, Moreno FS. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis [Internet]. Carcinogenesis. 2021 ; 42( 8): 1026–1036.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1093/carcin/bgab039
Artigo de periodico
Anthocyanins from purple maize (Zea mays L.) downregulate lipopolysaccharide-induced peritonitis in mice by modulating the MyD88 signaling pathway (2021)
Moreira, Vanessa ; Stanquevis, Regina; Amaral, Eduardo Pinheiro ; Lajolo, Franco Maria ; Hassimotto, Neuza Mariko Aymoto
Source: PharmaNutrition. Unidade: FCF
Subjects: MILHO, LIPOPOLISSACARÍDEOS, PIGMENTOS VEGETAIS, COMPOSTOS FENÓLICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOREIRA, Vanessa et al. Anthocyanins from purple maize (Zea mays L.) downregulate lipopolysaccharide-induced peritonitis in mice by modulating the MyD88 signaling pathway. PharmaNutrition, v. 16, p. 1-11 art. 100265, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.phanu.2021.100265. Acesso em: 15 nov. 2024.
APA
Moreira, V., Stanquevis, R., Amaral, E. P., Lajolo, F. M., & Hassimotto, N. M. A. (2021). Anthocyanins from purple maize (Zea mays L.) downregulate lipopolysaccharide-induced peritonitis in mice by modulating the MyD88 signaling pathway. PharmaNutrition, 16, 1-11 art. 100265. doi:10.1016/j.phanu.2021.100265
NLM
Moreira V, Stanquevis R, Amaral EP, Lajolo FM, Hassimotto NMA. Anthocyanins from purple maize (Zea mays L.) downregulate lipopolysaccharide-induced peritonitis in mice by modulating the MyD88 signaling pathway [Internet]. PharmaNutrition. 2021 ; 16 1-11 art. 100265.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.phanu.2021.100265
Vancouver
Moreira V, Stanquevis R, Amaral EP, Lajolo FM, Hassimotto NMA. Anthocyanins from purple maize (Zea mays L.) downregulate lipopolysaccharide-induced peritonitis in mice by modulating the MyD88 signaling pathway [Internet]. PharmaNutrition. 2021 ; 16 1-11 art. 100265.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.phanu.2021.100265

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Grupo de pesquisa

Funding Agencies